Lab Medicine Rounds Understanding COVID-Associated Coagulopathy
May 6, 2020
Ariella Marshall, an Associate Professor of Medicine specializing in hematology at Mayo Clinic, discusses the critical nature of COVID-associated coagulopathy. She explains how this condition differs from typical coagulopathies and highlights essential diagnostic markers, such as the soluble fibrin monomer test. Marshall shares insights on managing anticoagulation, emphasizing the role of prophylactic measures to prevent venous thromboembolism. Additionally, she reflects on key lessons learned from the pandemic, stressing the importance of personalized treatment strategies.
AI Snips
Chapters
Transcript
Episode notes
Importance of Recognizing COVID Coagulopathy
- COVID-associated coagulopathy shows elevated D-dimer, linked to poor outcomes and ICU admission risk.
- Recognizing it early helps predict clinical severity and mortality in COVID patients.
COVID Coagulopathy vs DIC
- COVID coagulopathy differs from classic DIC by elevated rather than low fibrinogen due to inflammation.
- It involves a cytokine storm with high IL-6, ferritin, and fibrinogen, unlike typical consumption coagulopathy.
Recommended Testing for COVID Coagulopathy
- Test hospitalized COVID patients for D-dimer, prothrombin time, and platelet count at minimum.
- Trend labs frequently in severe or ICU patients to monitor progression and support clinical decisions.